Render Target: STATIC
Render Timestamp: 2024-12-20T11:17:09.126Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-04-24 20:37:11.750
Product last modified at: 2024-06-07T08:00:10.452Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CD40 (Selicrelumab Biosimilar) Human mAb #32592

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa)
    Source/Isotype Human IgG2 kappa
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Description

    CD40 (Selicrelumab Biosimilar) Human mAb is a biosimilar antibody for Selicrelumab. Selicrelumab is a therapeutic human monoclonal antibody with agonistic activity on CD40.
    Endotoxin <0.1 EU/μg of antibody

    Product Usage Information

    This product is intended for research use only (RUO). Optimal dilutions/concentrations should be determined by the end user.

    Formulation

    Supplied in 1X PBS, BSA and Azide Free.

    Storage

    Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance.

    Specificity / Sensitivity

    CD40 (Selicrelumab Biosimilar) Human mAb was confirmed to bind to its intended target protein Selicrelumab using flow cytometry.

    Species Reactivity:

    Human

    Source / Purification

    CD40 (Selicrelumab Biosimilar) Human mAb is produced at Cell Signaling Technology. Selicrelumab is an antibody directed to bind to the extracellular domain of CD40.

    Background

    CD40, also known as tumor necrosis factor receptor superfamily member 5 (TNFRSF5), is a type I transmembrane protein expressed on the surface of B cells and professional antigen-presenting cells of the immune system, as well as on several non-hematopoietic cell types and cancers (1-4). CD40 interacts with CD40 ligand (CD40L/TNFSF5), which is expressed primarily on activated T cells but has also been reported on blood platelets, mast cells, basophils, NK cells, and B cells (5). Upon engagement with CD40L, CD40 signals through TNF receptor associated factors and MAP kinase signaling pathways, resulting in a wide variety of immune and inflammatory responses, including dendritic cell activation and cross-presentation, T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation (6-8). The CD40/CD40L axis is essential for the initiation and progression of cellular and humoral adaptive immunity, and is an important area of interest in the study of tumor immunology, neurodegenerative diseases, vascular diseases, and inflammatory disorders (9-12).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.